Alzheimer’s Disease

ICER

ICER plans to assess the comparative clinical effectiveness and value of aducanumab (Biogen) for the treatment of Alzheimer’s disease. The FDA is expected to make a decision on aducanumab in early 2021.

Date of review: May 2021

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer-review.org.

ASSOCIATED MEETING & MATERIALS

CTAF
May 7, 2021

TBA

The CTAF will convene virtually to deliberate and vote on evidence presented in ICER's report on Alzheimer's disease.

Key Dates

Associated Materials

09/29/2020 – 10/16/2020

10/21/2020

10/21/2020 – 11/10/2020
Public Comments

10/21/2020

11/18/2020
Revised Scoping Document

11/25/2020
Research Protocol

01/05/2021
Model Analysis Plan

03/01/2021
Draft Evidence Report

03/01/2021
Draft Voting Questions

03/01/2021 – 03/26/2021
Public Comments

04/23/2021
Revised Voting Questions

04/23/2021
Evidence Report

04/23/2021
Response to Public Comments

05/07/2021
Meeting Agenda

05/07/2021
Evidence Presentation

05/28/2021
Final Evidence Report and Meeting Summary

05/28/2021
Report-at-a-Glance

05/28/2021
Final Policy Recommendations


Key Dates

Associated Materials

Other Materials

Other Policy Development Group List